“The Dana-Farber Pathways platform enables busy oncologists to function as efficiently as possible by providing them at-their-fingertips access to predetermined treatment recommendations based on review of the most recent data by their peers,” said Joseph O. Jacobson, MD, MSc, Chief Quality Officer at the Dana-Farber Cancer Institute. “The pathways platform is easily accessible in the midst of a busy clinical practice, guides physicians to the recommended treatment in a visually intuitive way, provides one-click access to supporting literature and creates a regimen-specific consent form. Of equal importance, the platform facilitates the selection of off-pathway choices when the on-pathway recommendation is not the best option for the patient.”
During the recent American Society of Clinical Oncology (ASCO) annual meeting in Chicago, Philips showcased its capabilities to provide access to top-tier expert content for oncology decision making from Dana-Farber Pathways, including optional personalized therapies listing and recommended clinical trials matching to deliver guidance and trust from Dana-Farber to other locations and institutions around the country and around the world where patients receive care. Hear more from Dana-Farber’s Dr. David Jackman and Carole Tremonti on why one of the leading cancer institutes in the world chose Philips to power its Oncology Pathways to help improve cancer care.
More information on how Philips and Dana-Farber integrate data into informed treatment options is available here.
Philips IntelliSpace Precision Medicine Oncology Pathways powered by Dana-Farber is currently available in the U.S. and selected international markets.
Back to HCB News
